Clinical Trial Update: Docetaxel and Carboplatin Versus Docetaxel as Second Line Treatment in Patients With Non-Small-Cell Lung Carcinoma (NSCLC) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing docetaxel plus carboplatin versus docetaxel alone as second-line therapy in non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Hellenic Oncology Research Group | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED